Fc-less bispecific T-cell engagers have reached the immuno-oncology market but necessitate continual infusion due to rapid clearance from the circulation. This work introduces a programmable serum half-life extension platform based on fusion of human albumin sequences engineered with either null (NB)...
The cancer space has been aflutter with notable approvals so far this year, but there are several more candidates with significant data expected over the next four months. BioSpace takes a closer look.
The companies have begun Phase 3 trials of mRNA-4157 with Keytruda for people with stage III and IV melanoma. The Food and Drug Administration earlier this year designated the treatment as a breakthrough therapy in order to expedite the development and review of drugs meant to treat life-threat...
we know big biopharma is looking and hungry. We did not see big announcements such as Bristol Myers Squibb’s USD 74 billion Celgene deal, which dropped in the lead-up to the healthcare industry’s largest gathering in 2019. This year, many analysts expect a rebound for the life sciences...